Targeting ubiquitin in cancers

被引:15
作者
Dikic, Ivan
Crosetto, Nicola
Calatroni, Silvia
Bernasconi, Paolo
机构
[1] Goethe Univ Hosp, Inst Biochem 2, D-60590 Frankfurt, Germany
[2] Fdn IRCCS Policlin San Matteo, Dept Haematol, I-27100 Pavia, Italy
关键词
ubiquitin; multiple myeloma; leukaemia; lymphoma; bortezomib; Ub system-targeted drugs;
D O I
10.1016/j.ejca.2006.05.041
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ubiquitin (Ub) is a small protein modifier involved in cellular functions such as cell cycle, apoptosis, cell signalling, endocytosis, transcription and DNA repair. Ubiquitin operates as a reversible and highly versatile regulatory signal, which may be read and interpreted by an expanding number of Ub-binding domains (UBD). There is accumulating evidence that mutations or altered expression of ubiquitylating or de-ubiquitylating enzymes as well as of Ub-binding proteins affect crucial mediators of such functions and are found in several malignancies. Here we discuss how oncogenic alterations in the Ub system can be targeted by anti-cancer therapies. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3095 / 3102
页数:8
相关论文
共 58 条
[1]   A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue [J].
Akagi, T ;
Motegi, M ;
Tamura, A ;
Suzuki, R ;
Hosokawa, Y ;
Suzuki, H ;
Ota, H ;
Nakamura, S ;
Morishima, Y ;
Taniwaki, M ;
Seto, M .
ONCOGENE, 1999, 18 (42) :5785-5794
[2]   Ubiquitin-binding domains in Y-family polymerases regulate translesion synthesis [J].
Bienko, M ;
Green, CM ;
Crosetto, N ;
Rudolf, F ;
Zapart, G ;
Coull, B ;
Kannouche, P ;
Wider, G ;
Peter, M ;
Lehmann, AR ;
Hofmann, K ;
Dikic, I .
SCIENCE, 2005, 310 (5755) :1821-1824
[3]   The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy [J].
Blagosklonny, MV ;
Fojo, T ;
Bhalla, KN ;
Kim, JS ;
Trepel, JB ;
Figg, WD ;
Rivera, Y ;
Neckers, LM .
LEUKEMIA, 2001, 15 (10) :1537-1543
[4]   The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications [J].
Burger, AM ;
Seth, AK .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (15) :2217-2229
[5]  
CHANANKHAN A, 2005, HAEMATOLOGICA S2, V90, P633
[6]   A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib [J].
Chauhan, D ;
Catley, L ;
Li, GL ;
Podar, K ;
Hideshima, T ;
Velankar, M ;
Mitsiades, C ;
Mitsiades, N ;
Yasui, H ;
Letai, A ;
Ovaa, H ;
Berkers, C ;
Nicholson, B ;
Chao, TH ;
Neuteboom, STC ;
Richardson, P ;
Palladino, MA ;
Anderson, KC .
CANCER CELL, 2005, 8 (05) :407-419
[7]  
Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO
[8]  
2-Q
[9]   MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells [J].
Coll-Mulet, Llorenc ;
Iglesias-Serret, Daniel ;
Santidrian, Antonio F. ;
Cosialls, Ana M. ;
de Frias, Merce ;
Castano, Esther ;
Campas, Clara ;
Barragan, Montserrat ;
Fernandez de Sevilla, Alberto ;
Domingo, Alicia ;
Vassilev, Lyubomir T. ;
Pons, Gabriel ;
Gil, Joan .
BLOOD, 2006, 107 (10) :4109-4114
[10]   Oncogenic breakdowns in endocytic adaptor proteins [J].
Crosetto, N ;
Tikkanen, R ;
Dikic, I .
FEBS LETTERS, 2005, 579 (15) :3231-3238